BR112021024754A2 - Vesículas extracelulares microbianas secretadas - Google Patents

Vesículas extracelulares microbianas secretadas

Info

Publication number
BR112021024754A2
BR112021024754A2 BR112021024754A BR112021024754A BR112021024754A2 BR 112021024754 A2 BR112021024754 A2 BR 112021024754A2 BR 112021024754 A BR112021024754 A BR 112021024754A BR 112021024754 A BR112021024754 A BR 112021024754A BR 112021024754 A2 BR112021024754 A2 BR 112021024754A2
Authority
BR
Brazil
Prior art keywords
extracellular vesicles
microbial extracellular
secreted
secreted microbial
smevs
Prior art date
Application number
BR112021024754A
Other languages
English (en)
Inventor
Alicia Ballok
Andrea Itano
Baundauna Bose
Brian Goodman
J H Davitt Christopher
B Troy Erin
B Romano-Chernac Fabian
Holly Ponichtera
Loise Francisco-Anderson
Maria Sizova
Mark Bodmer
Nihal Okan
M R Carlton Sofia
A Cormack Taylor
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of BR112021024754A2 publication Critical patent/BR112021024754A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

vesículas extracelulares microbianas secretadas pedidos relacionados. a presente invenção refere-se a métodos e composições farmacêuticas relacionadas a vesículas extracelulares microbianas secretadas (smevs) que podem ser úteis como agentes terapêuticos.
BR112021024754A 2019-06-11 2020-06-11 Vesículas extracelulares microbianas secretadas BR112021024754A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962860049P 2019-06-11 2019-06-11
US201962860029P 2019-06-11 2019-06-11
US202062979545P 2020-02-21 2020-02-21
US202062991767P 2020-03-19 2020-03-19
PCT/US2020/037201 WO2020252144A1 (en) 2019-06-11 2020-06-11 Secreted microbial extracellular vesicles

Publications (1)

Publication Number Publication Date
BR112021024754A2 true BR112021024754A2 (pt) 2022-04-19

Family

ID=71950732

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112021024830A BR112021024830A2 (pt) 2019-06-11 2020-06-11 Vesículas extracelulares microbianas processadas
BR112021024754A BR112021024754A2 (pt) 2019-06-11 2020-06-11 Vesículas extracelulares microbianas secretadas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112021024830A BR112021024830A2 (pt) 2019-06-11 2020-06-11 Vesículas extracelulares microbianas processadas

Country Status (12)

Country Link
US (2) US20220249579A1 (pt)
EP (2) EP3982987A1 (pt)
JP (2) JP2022537684A (pt)
KR (2) KR20220020894A (pt)
CN (2) CN114096262A (pt)
AU (2) AU2020291434A1 (pt)
BR (2) BR112021024830A2 (pt)
CA (2) CA3143025A1 (pt)
CO (2) CO2022000040A2 (pt)
MX (2) MX2021015427A (pt)
TW (2) TW202128198A (pt)
WO (2) WO2020252149A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200118100A (ko) * 2018-02-06 2020-10-14 에벨로 바이오사이언시즈, 인크. 베일로넬라 박테리아를 이용한 암 및 면역 장애를 치료하기 위한 조성물 및 방법
KR102286042B1 (ko) * 2019-01-09 2021-08-03 주식회사 엠디헬스케어 데이노코커스 속 세균 유래 나노소포 및 이의 용도
WO2021252861A1 (en) * 2020-06-11 2021-12-16 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using megasphaera sp
EP4164666A2 (en) * 2020-06-11 2023-04-19 Evelo Biosciences, Inc. Compositions and methods for treating diseases and disorders using harryflintia acetispora
KR20230053609A (ko) * 2020-07-21 2023-04-21 에벨로 바이오사이언시즈, 인크. 신경염증성 질환에 대한 경구 요법으로서의 베일로넬라 파르불라 균주
WO2022061119A1 (en) * 2020-09-21 2022-03-24 Evelo Biosciences, Inc. Compositions and methods for modulating immune responses with prevotella histicola
KR20230137968A (ko) * 2021-01-26 2023-10-05 에벨로 바이오사이언시즈, 인크. 프레보텔라 세포외 소포체 제제
WO2022178209A1 (en) * 2021-02-19 2022-08-25 Evelo Biosciences, Inc. Compositions and methods for treating metabolic diseases and disorders using christensenellaceae bacteria
WO2022221183A1 (en) * 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) * 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
WO2023114300A1 (en) * 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023114293A1 (en) * 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle assays
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023239728A1 (en) * 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
AU2018298087A1 (en) * 2017-07-05 2020-01-23 Evelo Biosciences, Inc. Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis
TW201920648A (zh) * 2017-08-29 2019-06-01 美商艾弗洛生物科技股份有限公司 使用布勞特氏(blautia)菌株治療癌症
CN111148531A (zh) * 2017-09-08 2020-05-12 伊夫罗生物科学公司 细菌胞外囊泡
KR20200053532A (ko) * 2017-09-08 2020-05-18 에벨로 바이오사이언시즈, 인크. 프레보텔라로부터의 세포외 소포
EP3710023A1 (en) * 2017-11-14 2020-09-23 Evelo Biosciences, Inc. Compositions and methods for treating disease using a blautia strain
KR20200090189A (ko) * 2017-11-15 2020-07-28 에벨로 바이오사이언시즈, 인크. 면역조절 락토코쿠스 박테리아 균주를 사용하여 면역 장애를 치료하기 위한 조성물 및 방법
CN109580960A (zh) * 2019-01-14 2019-04-05 周明 细胞外囊泡的分离方法、以及检测细胞外囊泡表面标志物的方法和试剂盒

Also Published As

Publication number Publication date
CA3143036A1 (en) 2020-12-17
WO2020252144A1 (en) 2020-12-17
CO2022000040A2 (es) 2022-01-17
EP3982986A1 (en) 2022-04-20
KR20220020893A (ko) 2022-02-21
BR112021024830A2 (pt) 2022-04-12
CA3143025A1 (en) 2020-12-17
KR20220020894A (ko) 2022-02-21
US20220296654A1 (en) 2022-09-22
MX2021015429A (es) 2022-01-24
AU2020291003A1 (en) 2022-01-06
AU2020291434A1 (en) 2022-01-06
CO2022000041A2 (es) 2022-01-17
WO2020252149A1 (en) 2020-12-17
JP2022537684A (ja) 2022-08-29
JP2022538765A (ja) 2022-09-06
US20220249579A1 (en) 2022-08-11
EP3982987A1 (en) 2022-04-20
TW202114718A (zh) 2021-04-16
CN114096262A (zh) 2022-02-25
CN114650831A (zh) 2022-06-21
MX2021015427A (es) 2022-01-24
TW202128198A (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
BR112021024754A2 (pt) Vesículas extracelulares microbianas secretadas
CO2020004233A2 (es) Vesículas extracelulares bacterianas
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CY1120529T1 (el) Προφαρμακα φουμαρικων αλατων και η χρηση τους στην αγωγη ποικιλων νοσων
BR112021016605A2 (pt) Preparações de membrana bacteriana
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CL2018002703A1 (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). (divisional solicitud 201401291)
PE20200617A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39
CO7111285A2 (es) Composiciones pesticidas y procesos relacionados con ellas
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
CO6741218A2 (es) Composición pesticida y procesos relacionados con el mismo
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2019005925A (es) Composiciones de alergenos liquidas y metodos para la preparacion de las mismas.
WO2020123773A3 (en) Anellosomes for delivering secreted therapeutic modalities
DOP2019000221A (es) Derivados de pirazol como inhibidores de bromodominio
CL2018002368A1 (es) Formulaciones de oritavancina
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
AR119272A1 (es) Vesículas extracelulares microbianas secretadas
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]